Novartis gears up for key expansions of 3 cancer drugs
Novartis pauses enrollment for Kisqali breast cancer trials to align with nitrosamine guidelines
Alembic Pharmaceuticals Ltd on Monday said it received tentative approval for generic Ribociclib tablets used in the treatment of breast cancer in the March quarter. The tentative approval by the US Food & Drug Administration (USFDA) was for Ribociclib tablets of strength 200 mg, Alembic Pharmaceuticals said in a regulatory filing.
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in...
Palazestrant (OP-1250) in combination with the CDK 4/6 inhibitors, ribociclib and palbociclib, demonstrated no significant drug-drug interaction, no dose-limiting toxicities and a tolerability profile...
Novartis is getting more optimistic about its midterm sales potential, thanks to bullish estimates for some blockbuster drugs.
Late-breaking final iDFS analysis from NATALEE investigating Kisqali® (ribociclib) in broad population of patients with stage II and III HR+/HER2- early breast cancer, including those with...
Late-breaking NATALEE subgroup analysis to be presented at ESMO shows invasive disease-free survival (iDFS) benefit remains consistent in all subgroups, including in patients with stage II tumors,...
FRANKFURT, June 2 (Reuters) - Novartis (NOVN.S) breast cancer drug Kisqali cut the risk of recurrence by more than 25% in a pivotal trial on women diagnosed at an early stage, positioning the Swiss drugmaker to win new patients and but facing strong competition from Eli Lilly (LLY.N).
SAN FRANCISCO, May 30, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (œOlema, œOlema Oncology, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...